Hoyoung Huh - Net Worth and Insider Trading

Hoyoung Huh Net Worth

The estimated net worth of Hoyoung Huh is at least $74,009 dollars as of 2024-06-05. Hoyoung Huh is the Director, 10% Owner of Peak Bio Inc and owns about 8,605,682 shares of Peak Bio Inc (PKBO) stock worth over $74,009. Details can be seen in Hoyoung Huh's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Hoyoung Huh has not made any transactions after 2023-09-14 and currently still holds the listed stock(s).

Transaction Summary of Hoyoung Huh

Hoyoung Huh Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Hoyoung Huh owns 8 companies in total, including Pliant Therapeutics Inc (PLRX) , Eidos Therapeutics Inc (EIDX) , and CytomX Therapeutics Inc (CTMX) among others .

Click here to see the complete history of Hoyoung Huh’s form 4 insider trades.

Insider Ownership Summary of Hoyoung Huh

Ticker	Comapny	Transaction Date	Type of Owner
PLRX	Pliant Therapeutics Inc	2020-06-02	director
EIDX	Eidos Therapeutics Inc	2018-06-22	director
CTMX	CytomX Therapeutics Inc	2018-06-13	director
		2010-05-19	director
		2013-01-31	director & 10 percent owner
		2007-05-18	COO & Head of PEGylation Bus
		2023-09-14	director
		2022-11-01	director

Hoyoung Huh Latest Holdings Summary

Hoyoung Huh currently owns a total of 1 stock. Hoyoung Huh owns 8,605,682 shares of Peak Bio Inc (PKBO) as of September 14, 2023, with a value of $74,009.

Latest Holdings of Hoyoung Huh

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
PKBO	Peak Bio Inc	2023-09-14	8,605,682	0.01	74,009

Holding Weightings of Hoyoung Huh

Hoyoung Huh Form 4 Trading Tracker

According to the SEC Form 4 filings, Hoyoung Huh has made a total of 3 transactions in Peak Bio Inc (PKBO) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Peak Bio Inc is the acquisition of 50,000 shares on September 14, 2023, which cost Hoyoung Huh around $13,500.

Insider Trading History of Hoyoung Huh

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Hoyoung Huh Trading Performance

GuruFocus tracks the stock performance after each of Hoyoung Huh's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Hoyoung Huh is -75.07%. GuruFocus also compares Hoyoung Huh's trading performance to market benchmark return within the same time period. The performance of stocks bought by Hoyoung Huh within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Hoyoung Huh's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Hoyoung Huh

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-62.81
Relative Return to S&P 500(%)	-59.03

Hoyoung Huh Ownership Network

Ownership Network List of Hoyoung Huh

No Data

Ownership Network Relation of Hoyoung Huh

Hoyoung Huh Owned Company Details

What does Pliant Therapeutics Inc do?

Who are the key executives at Pliant Therapeutics Inc?

Hoyoung Huh is the director of Pliant Therapeutics Inc. Other key executives at Pliant Therapeutics Inc include Chief Business Officer Hans Hull , Chief Medical Officer Eric Lefebvre , and Chief Financial Officer Keith Lamont Cummings .

Pliant Therapeutics Inc (PLRX) Insider Trades Summary

Over the past 18 months, Hoyoung Huh made no insider transaction in Pliant Therapeutics Inc (PLRX). Other recent insider transactions involving Pliant Therapeutics Inc (PLRX) include a net sale of 405,422 shares made by Bernard Coulie , a net sale of 58,128 shares made by Mike Ouimette , and a net sale of 122,248 shares made by Eric Lefebvre .

In summary, during the past 3 months, insiders sold 0 shares of Pliant Therapeutics Inc (PLRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 745,379 shares of Pliant Therapeutics Inc (PLRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 745,379 shares.

Pliant Therapeutics Inc (PLRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pliant Therapeutics Inc Insider Transactions

No Available Data

What does Eidos Therapeutics Inc do?

Who are the key executives at Eidos Therapeutics Inc?

Hoyoung Huh is the director of Eidos Therapeutics Inc. Other key executives at Eidos Therapeutics Inc include director & Chief Scientific Officer Uma Sinha , Senior Vice President & Finance Franco Valle , and Chief Business Officer Cameron Turtle .

Eidos Therapeutics Inc (EIDX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eidos Therapeutics Inc (EIDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eidos Therapeutics Inc (EIDX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eidos Therapeutics Inc (EIDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eidos Therapeutics Inc Insider Transactions

No Available Data

What does CytomX Therapeutics Inc do?

Who are the key executives at CytomX Therapeutics Inc?

Hoyoung Huh is the director of CytomX Therapeutics Inc. Other key executives at CytomX Therapeutics Inc include SVP & Chief Scientific Officer Marcia Belvin , SVP & Finance and Accounting Christopher Ogden , and Chief Financial Officer Jeffrey B Landau .

CytomX Therapeutics Inc (CTMX) Insider Trades Summary

Over the past 18 months, Hoyoung Huh made no insider transaction in CytomX Therapeutics Inc (CTMX). Other recent insider transactions involving CytomX Therapeutics Inc (CTMX) include a net sale of 55,496 shares made by Sean A. Mccarthy , a net sale of 16,868 shares made by Lloyd A Rowland , and a net sale of 16,235 shares made by Jeffrey B Landau .

In summary, during the past 3 months, insiders sold 47,819 shares of CytomX Therapeutics Inc (CTMX) in total and bought 0 shares, with a net sale of 47,819 shares. During the past 18 months, 121,072 shares of CytomX Therapeutics Inc (CTMX) were sold and 5,000 shares were bought by its insiders, resulting in a net sale of 116,072 shares.

CytomX Therapeutics Inc (CTMX)'s detailed insider trading history can be found in Insider Trading Tracker table.

CytomX Therapeutics Inc Insider Transactions

No Available Data

What does Geron Corp do?

Who are the key executives at Geron Corp?

Hoyoung Huh is the director of Geron Corp. Other key executives at Geron Corp include EVP & Chief Financial Officer Michelle Robertson , EVP & Chief Legal Officer Scott Alan Samuels , and director & Chief Executive Officer John A Scarlett .

Geron Corp (GERN) Insider Trades Summary

Over the past 18 months, Hoyoung Huh made no insider transaction in Geron Corp (GERN). Other recent insider transactions involving Geron Corp (GERN) include a net sale of 1,340,000 shares made by John A Scarlett , a net sale of 400,000 shares made by Olivia Kyusuk Bloom , and a net sale of 384,719 shares made by Andrew J Grethlein .

In summary, during the past 3 months, insiders sold 0 shares of Geron Corp (GERN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,194,719 shares of Geron Corp (GERN) were sold and 13,186 shares were bought by its insiders, resulting in a net sale of 2,181,533 shares.

Geron Corp (GERN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Geron Corp Insider Transactions

No Available Data

What does Rezolute Inc do?

Who are the key executives at Rezolute Inc?

Hoyoung Huh is the director & 10 percent owner of Rezolute Inc. Other key executives at Rezolute Inc include Chief Medical Officer Brian Kenneth Roberts , director & 10 percent owner & Chief Executive Officer Nevan C Elam , and 10 percent owner Handok, Inc. .

Rezolute Inc (RZLT) Insider Trades Summary

Over the past 18 months, Hoyoung Huh made no insider transaction in Rezolute Inc (RZLT). Other recent insider transactions involving Rezolute Inc (RZLT) include a net purchase of 39,000 shares made by Brian Kenneth Roberts , a net purchase of 124,351 shares made by Daron Evans , and a net purchase of 115,450 shares made by Young-jin Kim .

In summary, during the past 3 months, insiders sold 0 shares of Rezolute Inc (RZLT) in total and bought 207,901 shares, with a net purchase of 207,901 shares. During the past 18 months, 0 shares of Rezolute Inc (RZLT) were sold and 283,801 shares were bought by its insiders, resulting in a net purchase of 283,801 shares.

Rezolute Inc (RZLT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rezolute Inc Insider Transactions

No Available Data

What does Nektar Therapeutics do?

Who are the key executives at Nektar Therapeutics?

Hoyoung Huh is the COO & Head of PEGylation Bus of Nektar Therapeutics. Other key executives at Nektar Therapeutics include SVP & General Counsel Mark Andrew Wilson , Chief R&D Officer Jonathan Zalevsky , and director & President & CEO Howard W Robin .

Nektar Therapeutics (NKTR) Insider Trades Summary

Over the past 18 months, Hoyoung Huh made no insider transaction in Nektar Therapeutics (NKTR). Other recent insider transactions involving Nektar Therapeutics (NKTR) include a net sale of 116,554 shares made by Howard W Robin , a net sale of 55,993 shares made by Jonathan Zalevsky , and a net sale of 44,084 shares made by Mark Andrew Wilson .

In summary, during the past 3 months, insiders sold 86,265 shares of Nektar Therapeutics (NKTR) in total and bought 0 shares, with a net sale of 86,265 shares. During the past 18 months, 291,616 shares of Nektar Therapeutics (NKTR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 291,616 shares.

Nektar Therapeutics (NKTR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Nektar Therapeutics Insider Transactions

No Available Data

What does Peak Bio Inc do?

Who are the key executives at Peak Bio Inc?

Hoyoung Huh is the director of Peak Bio Inc. Other key executives at Peak Bio Inc include General Counsel Peter David Mccabe , 10 percent owner Sbi Kis 2016-1 Fund , and 10 percent owner 2014 Kif-sbi It Investment Fund .

Peak Bio Inc (PKBO) Insider Trades Summary

Over the past 18 months, Hoyoung Huh made 3 insider transaction in Peak Bio Inc (PKBO) with a net purchase of 190,250.

In summary, during the past 3 months, insiders sold 0 shares of Peak Bio Inc (PKBO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Peak Bio Inc (PKBO) were sold and 190,250 shares were bought by its insiders, resulting in a net purchase of 190,250 shares.

Peak Bio Inc (PKBO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Peak Bio Inc Insider Transactions

No Available Data

What does Ignyte Acquisition Corp do?

Who are the key executives at Ignyte Acquisition Corp?

Hoyoung Huh is the director of Ignyte Acquisition Corp. Other key executives at Ignyte Acquisition Corp include General Counsel Peter David Mccabe , 10 percent owner Sbi Kis 2016-1 Fund , and 10 percent owner 2014 Kif-sbi It Investment Fund .

Ignyte Acquisition Corp (IGNYU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ignyte Acquisition Corp (IGNYU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ignyte Acquisition Corp (IGNYU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ignyte Acquisition Corp (IGNYU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ignyte Acquisition Corp Insider Transactions

No Available Data

Hoyoung Huh Mailing Address

Above is the net worth, insider trading, and ownership report for Hoyoung Huh. You might contact Hoyoung Huh via mailing address: C/o Nektar Therapeutics, 201 Industrial Road, San Carlos Ca 94070.

Discussions on Hoyoung Huh

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.